ISSUE: There have been major strides in biopharmaceutical research and advances in prevention, screening, diagnosis and treatment in recent decades, thanks to investment from the public and private sectors. However, all countries have voiced concern over the escalating prices and affordability of medicines and especially the budgetary impact of novel medicines. This has led to restricted patient access, increased inequities, and financial hardship when health systems are already under significant financial and fiscal constraints because of the economic context and socioeconomic recovery from COVID-19.

At the 72nd session of the WHO Regional Committee for Europe in September 2022, the WHO Regional Office for Europe, in agreement with Member States, issued a statement of intent to act as a neutral convenor for the establishment of a platform for collaboration, to improve patient access to novel high-cost medicines. The WHO Europe’s Access to Novel Medicines Platform (NMP) will enable Member States, non-State actors and other partners to coordinate, collaborate, prioritize and align efforts to deliver solutions to improve access for patients.

OVERVIEW: Tarang will introduce the NMP with its aims, objectives and technical areas and introduce the different stakeholders on the panel. 5 mins

Meindert will present the challenges NICE is facing in providing access to novel medicines to England and Wales, and what they hope to resolve through international cooperation. 10 mins

Simone will present the challenges patients have in accessing orphan drugs and what possible solutions EURODIS would like to see move forward through the NMP. 10 mins

Thomas will present the barriers industry is facing in providing access to novel medicines and what EFPIA hopes to achieve through participation in the NMP. 10 mins

The floor will be opened for Q&A and discussion with the panelists. 20 mins

Closing remarks and final comments by the panel. 5 mins